Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 8/20 | 0.33 |
| ▸ | MAOB | P27338 | 8/20 | 0.33 |
| ▸ | KDM1A | O60341 | 8/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27002643 | 0.67 | MAOA (0.45) | MAOAMAOBKDM1ARCOR1 | |
| SCHEMBL28536932 | 0.66 | TAAR1 (0.40) | ATMMAOAMAOBKDM1ARCOR1 | |
| SCHEMBL10239279 | 0.66 | KMT2A (0.36) | ATMDPP4MAOAMAOBKDM1A | |
| SCHEMBL9957112 | 0.65 | TAAR1 (0.36) | DPP4MAOAMAOBKDM1AKMT2A | |
| SCHEMBL13281096 | 0.65 | USP2 (0.35) | LMNAKMT2A | |
| SCHEMBL2474184 | 0.65 | MAOA (0.52) | MAOAMAOBKDM1ARCOR1LMNA | |
| SCHEMBL9957480 | 0.64 | GRIN2B (0.40) | KMT2A | |
| SCHEMBL516000 | 0.62 | MAOA (0.46) | MAOAMAOBKDM1ARCOR1 | |
| SCHEMBL15294479 | 0.62 | LMNA (0.37) | ATMLMNAKMT2ASIGMAR1 | |
| SCHEMBL28206843 | 0.62 | MAOA (0.49) | MAOAMAOBKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654748-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9351965-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2654748-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130261125-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-10-03 | — | — | US | disclosed |
| WO-2012087772-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261125-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MAPK3, MAPK1, MAP3K1 | ATM 400/4885DPP4 3707/4885MAOA 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.